Pharmacotherapy of bladder dysfunction — past, present and future
Overactive bladder (OAB) encompasses a variety of conditions that may necessitate different therapeutic strategies. This diversity is evident in the wide range of medications used over the past five decades. Unfortunately, we have too few tools to identify individual conditions and even less informa...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Continence Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772974525000031 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850103725019889664 |
|---|---|
| author | Karl-Erik Andersson |
| author_facet | Karl-Erik Andersson |
| author_sort | Karl-Erik Andersson |
| collection | DOAJ |
| description | Overactive bladder (OAB) encompasses a variety of conditions that may necessitate different therapeutic strategies. This diversity is evident in the wide range of medications used over the past five decades. Unfortunately, we have too few tools to identify individual conditions and even less information about which condition is best served by which treatment. Many of the drugs have been discontinued primarily due to an unfavorable balance between efficacy and adverse effects. As a result, current treatment guidelines primarily recommend antimuscarinics and β3-adrenoceptor agonists, with intravesical botulinum toxin injections as a second-line option. While these treatments have documented efficacy, their use is often limited by side effects, adherence challenges, and persistence issues. Personalized treatment approaches may help optimize the use of these medications. However, there is a need for improved therapies, and many promising future therapeutic alternatives can be discussed. However, there seem to be no drugs ready for immediate clinical introduction. |
| format | Article |
| id | doaj-art-95fcbb4d2f6b4310a389fc9a8ffd002d |
| institution | DOAJ |
| issn | 2772-9745 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Continence Reports |
| spelling | doaj-art-95fcbb4d2f6b4310a389fc9a8ffd002d2025-08-20T02:39:28ZengElsevierContinence Reports2772-97452025-06-011410008010.1016/j.contre.2025.100080Pharmacotherapy of bladder dysfunction — past, present and futureKarl-Erik Andersson0Correspondence to: Institute of Laboratory Medicine, Lund University, Lund, Sweden.; Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, United States of America; Institute of Laboratory Medicine, Lund University, Lund, SwedenOveractive bladder (OAB) encompasses a variety of conditions that may necessitate different therapeutic strategies. This diversity is evident in the wide range of medications used over the past five decades. Unfortunately, we have too few tools to identify individual conditions and even less information about which condition is best served by which treatment. Many of the drugs have been discontinued primarily due to an unfavorable balance between efficacy and adverse effects. As a result, current treatment guidelines primarily recommend antimuscarinics and β3-adrenoceptor agonists, with intravesical botulinum toxin injections as a second-line option. While these treatments have documented efficacy, their use is often limited by side effects, adherence challenges, and persistence issues. Personalized treatment approaches may help optimize the use of these medications. However, there is a need for improved therapies, and many promising future therapeutic alternatives can be discussed. However, there seem to be no drugs ready for immediate clinical introduction.http://www.sciencedirect.com/science/article/pii/S2772974525000031Anticholinergicsβ3-adrenoceptor agonistsBotulinum toxinUrine storage dysfunctionOveractive bladder |
| spellingShingle | Karl-Erik Andersson Pharmacotherapy of bladder dysfunction — past, present and future Continence Reports Anticholinergics β3-adrenoceptor agonists Botulinum toxin Urine storage dysfunction Overactive bladder |
| title | Pharmacotherapy of bladder dysfunction — past, present and future |
| title_full | Pharmacotherapy of bladder dysfunction — past, present and future |
| title_fullStr | Pharmacotherapy of bladder dysfunction — past, present and future |
| title_full_unstemmed | Pharmacotherapy of bladder dysfunction — past, present and future |
| title_short | Pharmacotherapy of bladder dysfunction — past, present and future |
| title_sort | pharmacotherapy of bladder dysfunction past present and future |
| topic | Anticholinergics β3-adrenoceptor agonists Botulinum toxin Urine storage dysfunction Overactive bladder |
| url | http://www.sciencedirect.com/science/article/pii/S2772974525000031 |
| work_keys_str_mv | AT karlerikandersson pharmacotherapyofbladderdysfunctionpastpresentandfuture |